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Behavioral Risk Factor Surveillance System (BRFSS) for New Mexico (NM) in which 
self-reported health status was measured on a 5-point scale of poor to excellent. For 
the purpose of this study we dichotomized self-reported health into 2 categories: 
good (good, very good, and excellent) and poor (fair and poor). Propensity score 
model of 13 variables accounting for socioeconomic factors, disease status, and 
exercise behavior was used to match obese (body mass index (BMI) ≥ 30 kg/m2) indi-
viduals with non-obese (BMI < 30 kg/m2).We used the STATA command psmatch2 
to perform 1:1 nearest neighbor matching without replacement, and caliper width 
was set at 0.001. Adequacy of matching was assessed by estimating the standardized 
differences between obese and non-obese individuals for all variables. Self-reported 
health was compared between the 2 groups using the McNemar’s test for matched 
comparison. Results: We identified 2310 obese individuals (26%) and 6671 non-
obese individuals (74%) in the database. Obese individuals were significantly dif-
ferent from non-obese in nearly all baseline characteristics. After 1:1 propensity 
score matching (n = 3512), obese individuals were significantly more likely to report 
poor health compared to non-obese individuals (Odds ratio = 1.45, 95% confidence 
interval: 1.23-1.72, p< 0.001).All standardized differences between groups were < 10% 
suggesting and adequate matching. ConClusions: Among propensity-matched 
individuals, those with obesity are more likely to rate their health as poor compared 
to non-obese individuals. Continuing efforts are needed to fight obesity epidemic 
both locally and nationally to improve overall quality of life.
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objeCtives: To examine the effect of factor IX concentrate consumption on self/
parent-proxy reported health status among persons with hemophilia B. Methods: 
Data were obtained from the Hemophilia Utilization Group Study Part Vb (HUGS 
Vb), a prospective, multi-center observational study evaluating burden of illness 
among a US hemophilia B population who obtain care at Hemophilia Treatment 
Centers. Health status was assessed using a visual analogue scale (VAS) at initial 
interview and at two-year follow-up visits. A clinically meaningful improvement in 
health status was defined as an increase of > 7 in VAS score. Annual factor concen-
trate consumption was estimated using 2 years of dispensing records. Propensity 
score matching (PSM) was applied to adjust for potential selection bias between 
persons with high (≥ 5000 IU/kg/yr) and low (< 5000 IU/kg/yr) factor consumption. 
Age, disease severity, treatment regimen and bleeding frequency were included 
in the propensity score model. Results: After applying PSM, mean age in the 
high (n= 25, 20 severe) and low factor consumption (n= 25, 21 severe) groups were 
14.5±11.6 and 14.3±11.3, respectively. The average bleeding rates were 7.4±6.6 and 
7.2±7.8 per year correspondingly. The proportion of participants treated with pro-
phylactic therapy was 64% in both groups. On average, persons with high factor 
consumption reported greater (1.96±15.48) VAS score changes than those with low 
factor consumption. Among persons with VAS< 93 at baseline (n= 34), 14 participants 
reported a clinically meaningful improvement in VAS after 2 years. The propor-
tion of participants who reported a clinically meaningful improvement was greater 
among persons in the high consumption group than in the low consumption group 
(50% vs. 35%). ConClusions: Due to the small sample size, regression was not 
performed to show the independent relationship between health status and factor 
consumption. However, persons using > 5000 IU/kg/yr of factor tend to report greater 
improvement in health status.
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objeCtives: Improvements in health-related quality of life (HRQoL) with epratu-
zumab (a monoclonal antibody targeting CD22) have been reported in patients with 
systemic lupus erythematosus (SLE) in the ALLEVIATE trials from Week 12 to 4 
years. In the EMBLEM™ dose-ranging, phase IIb, randomized controlled trial in SLE, 
epratuzumab resulted in clinically-relevant improvements in disease activity. We 
report HRQoL data from EMBLEM™ and its open-label extension (OLE). Methods: 
In EMBLEM™, patients with moderate-to-severe SLE (≥ 1 BILAG 2004 A or ≥ 2 Bs) were 
randomized to placebo (PBO) or epratuzumab (cumulative dose [cd] 200, 800, 2400 or 
3600mg divided every other week, or 600mg every week), plus standard of care (SOC). 
Patients who completed 12 weeks or discontinued due to lack of efficacy after ≥ 8 
weeks were eligible for OLE (1200mg epratuzumab at Weeks 0,2 of 12-week cycles). 
HRQoL was assessed using Short Form-36 (SF-36) v2.0. Data are reported to the end 
of EMBLEM™ and OLE Weeks 48 and 108. Mean changes and % patients reporting 
improvements ≥ minimum clinically important differences (MCID) (increases from 
baseline ≥ 5.0-points in domain and ≥ 2.5-points in physical and mental compo-
nent scores [PCS and MCS]) are presented. Results: Mean PCS and MCS scores 
across all groups increased from baseline through EMBLEM™ Week 12, with greater 
increases in the PBO group. Longer epratuzumab treatment during OLE resulted 
in clinically meaningful changes in HRQoL vs EMBLEM™ baseline. Mean PCS/MCS 
scores were 34.2/36.1, 38.7/40.0, 40.1/41.6 and 40.5/40.9 at EMBLEM™ baseline, OLE 
screening, Week 48 and Week 108, respectively. At OLE Week 108 70.8% and 59.3% 
of patients reported improvements ≥ MCID in PCS and MCS scores. ConClusions: 
therapeutic areas (classified according to the ICD-10) and 67 different indications. 
The most represented therapeutic areas were neoplasms (28 products, 40.6%) and 
endocrine, nutritional and metabolic diseases (21 products, 30.4%). Out of the 69 
products, 14 had a PRO claim (20.3% – in comparison, for all EMA products, the 
percentage is 26.9%). PROs identified in the claims were assessing function (e.g., 
physical functioning), symptoms (e.g., pain) and quality of life (QOL). Corresponding 
therapeutic areas and indications were neoplasms (trabectedin, ofatumumab, 
ruxolitinib), endocrine diseases (aztreonam lysine, ivacaftor, tafamidis), nervous 
system diseases (stiripentol, rufinamide), blood diseases (eculizumab, icatibant), 
pulmonary arterial hypertension (bosentan monohydrate, ambrisentan), cryopyrin-
associated periodic syndromes (rilonacept), and severe pain (ziconotide). Within 
these 14 products, four have a QOL claim (28.6%): two for neoplasms [trabectedin 
(ovarian cancer) – no differences between treatment in QOL; and ruxolitinib (mye-
olofibrosis) - improvement of QOL], one in diseases of the blood [eculizumab (two 
indications: paroxysmal nocturnal haemoglobinuria and atypical haemolytic urae-
mic syndrome - improvement of QOL], and one in endocrine disease [tafadimis 
(amyloidosis) – improvement of QOL]. ConClusions: The number of PRO claims in 
orphan medicines is comparable to the number of PRO claims in all EMA products. 
Various concepts are assessed, with QOL representing almost 30% of the claims.
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objeCtives: To estimate direct and indirect costs associated with hand, foot and 
mouth disease (HFMD) in China. Methods: Data were obtained from a nation-
wide telephone survey of family member of patients with HFMD from Dec, 2013 
to Jan, 2014. Patients’ numbers were from national infection disease surveillance 
database. Patients were eligible for the survey if they aged from 6 months to 5 years, 
had lab-confirmed as EV71, CoxA16 or other Enterovirus infection and without any 
underlying disease. HFMD-related outpatient and inpatient utilization and costs 
and direct non-medical costs were recorded. Indirect costs resulting from produc-
tivity loss due to absenteeism were estimated using the average income in China. 
All costs were reported in 2012 US dollar using the exchange rate of 6.18 Chinese 
Yuan to 1 USD. Results: A total of 3500 patients were included with 34.3% female. 
The number of mild, severe and death cases were 2259(64.54%), 1170(33.43%) and 
71(2.03%). 2352(67.23%) of patients received inpatient treatment. The mean direct 
medical costs were $966. Inpatient costs were $904, accounting for 93.5% of direct 
medical costs. The rest were attributed to outpatient and medications purchased 
from retail pharmacies. Mean direct non-medical costs were $67, including $20 
nutrition costs and $47 transportation. Mean costs associated with productivity 
loss were $170 and $55 (urban and rural respectively). ConClusions: HFMD poses 
substantial economic burden to payers, patients and society. The majority of total 
costs are attributed to direct medical costs but indirect costs from productivity loss 
are also substantial.
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objeCtives: The purpose of this literature review was to identify existing patient 
reported outcome (PRO) instruments, instrument items, and concepts employed 
in studies of health-related quality of life (HRQoL) and PROs in anemia of ESRD. 
The results will aid the development of a PRO for the assessment of HRQoL in this 
therapeutic area. Methods: Relevant abstracts for inclusion were identified via 
a search in OVID (MEDLINE 1946 to present; EMBASE 1988 to present) using terms 
related to: anemia, HRQoL, PRO, ESRD, chronic kidney disease (CKD), and renal insuf-
ficiency. Results were limited to English-language, non-animal studies, and adult 
samples. Articles focusing on treatment effects and non-relevant diseases, confer-
ence abstracts and duplicate articles were excluded. Results: The search identified 
1764 abstracts. 1752 were excluded based on pre-specified criteria. Only 12 met the 
inclusion criteria. No ESRD anemia-specific PROs were identified. The most fre-
quently utilized PROs applied in ESRD anemia included the Kidney Disease Quality 
of Life and the Kidney Disease Quality of Life Short Form. Key concepts reflected 
direct patient experiences and disease impacts, and covered three domains: physi-
cal, mental/emotional, and social. Specific concepts within the domain of physical 
health included physical function, pain, fatigue, sleep disturbance, and sexual func-
tion. Concepts within the domain of mental/emotional health included emotional 
distress, cognitive effects, and satisfaction with life. Concepts within the domain 
of social health included ability or willingness to participate in social activities, and 
disease impacts on social relationships and work status. ConClusions: No PROs 
developed in ESRD-related anemia or published studies exploring HRQoL of anemic 
ESRD patients were found. The results of this literature review highlight the absence 
of in-depth qualitative examinations of patient experiences of ESRD-related anemia, 
as well as the lack of disease-specific PRO instruments. Relevant concepts identi-
fied may be useful to inform the development of ESRD anemia-specific PRO tools.
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objeCtives: Within New Mexico (NM) half of adults are either overweight or obese. 
Obesity is associated with low socioeconomic status, sedentary life style and several 
diseases; all pose a threat on general health. In order to rule out potential confound-
ing, we use propensity score matching to compare self-reported health of obese 
individuals with those of non-obese. Methods: We utilized data from the 2011 
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was categorized according to WHO classifications. Total direct medical costs were 
assessed for transplantation in terms of charges and payments. Costs were stand-
ardized to 2012 U.S. dollars. Univariate analyses of covariates were assessed for asso-
ciation with log-transformed charges and payments and significant variables were 
included in multivariate regression analysis. Base charges and payments include 
covariates at mean values and based on low risk characteristics. Results: In mul-
tivariate analysis, DD base charges at transplant were $155,906 (adjusted R2 0.314). 
BMI > 40 and BMI 35 – 39.9 was associated with an additional $13,3662 (p< 0.0001) 
and $4,107 (p= 0.005) at transplant, respectively. BMI 18.5 – 24.9 was attributed to 
significantly less charges of $2,168 (p= 0.016). Base reimbursements at transplant 
were $36,315 (adjusted R2 0.229). Elevated BMI was not attributed at any additional 
reimbursements, however BMI 18.5 – 24.9 had additional reimbursements of $660 
(p< 0.0001). For LD, base charges were $151,291(adjusted R2 0.312) and BMI 30 – 35.9 
was associated with an additional $3,675 (p= 0.018) at transplant. Base reimburse-
ments were $38,361(adjusted R2 0.239). Elevated BMI was not a significant independ-
ent factor additional reimbursement. ConClusions: Increased BMI is a significant 
factor in the amount of health resources utilized for kidney transplantation. While 
elevated BMI results in significant greater costs to hospitals, no additional reim-
bursement from Medicare was observed. These findings may play a factor in nega-
tive selection against candidates with higher BMI at the time of transplantation.
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objeCtives: Infantile haemangioma (IH) appears in the first few days of life, and 
develops over time. Certain types of IH cause significant functional impairment and 
aesthetic. The objective of this work was to estimate (in children under the age of 
two years) hospital stay length for IH previous to and subsequent to introduction of 
propranolol as haemangioma treatment. Methods: Analysis of the PMSI database 
covered two periods: the first previous to propranolol use (2006) and the second 
more recent (2011) during which use of propranolol became widespread. In the 
PMSI database, haemangioma can be found under primary diagnosis (or related) or 
associated, it is normal to carry out economic assessments on the PD. Results: In 
2006, 1,205 children were admitted to hospital for IH, thus generating 1,758 hospital 
stays. Day hospital admissions represent 24%. In 2011, 1,712 children were admitted 
to hospital for IH, thus generating 2,136 hospital stays,. Day hospital admissions 
represent 30%. The average length of stay, with haemangioma as primary diagno-
sis, decreased from 2.44days in 2006 to 1.16days on average in 2011, representing 
a 50% decrease. We note that DRG differ between 2006 and 2011, suggesting that 
the diagnosis is best determined. ConClusions: Infantile haemangioma has a 
significant medical and financial impact. A recent assessment conducted in France 
in five hospitals treating IH, considered that the average cost of treatment (accord-
ing to the health insurance fund) of children with haemangioma reached € 6,407.00 
on average. The highest expenditure item was hospitalisation at an average cost of 
€ 5,337.00 (equivalent to 83% of the total average cost). A reduction in the length of 
hospital stays, subsequent to propranolol use, of almost 50% as demonstrated by 
the PMSI, should have a significant effect on treatment costs.
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objeCtives: Psoriasis (PsO) is a chronic, recurrent, immune-mediated disease often 
treated with biologic therapies. However, understanding of prescription initiation of 
biologics for psoriasis is limited. The current study evaluates patient and provider 
characteristics in treatment-naïve PsO patients prescribed either exclusively oral 
or biologic-containing regimens. Methods: A retrospective database analysis was 
performed using Humedica electronic medical record data for adult patients with at 
least one diagnosis for PsO and no prior history of PsO or PsO-related therapy within 
12 months prior to index date. Eligible patients were classified based on initial 
prescription as (1) oral only or (2) biologics (including oral and biologics as combi-
nation treatment). Patients’ demographic characteristics, comorbidities, disease 
status, prescriber specialty, and prescriber preference of biologics were compared 
for across both groups. Wilcoxon rank-sum and chi-squared tests were applied to 
variables of ordinal and nominal measure, respectively. Logistic regression was 
conducted to determine the variables associated with likelihood of initiation of 
a biologic treatment. Results: A total of 2,373 patients met inclusion criteria. Of 
these patients, 1,166 (49%) were classified as obese, 856 (36%) were diagnosed with 
psoriatic arthritis (PsA) and 261 (11%) were diagnosed with rheumatoid arthritis 
(RA). Male patients (OR= 1.47) and patients with comorbid PsA (OR= 1.51) were sig-
nificantly more likely to be prescribed biologics compared to female patients and 
those without comorbid PsA, respectively. However, older patients (≥ 65 years) were 
significantly less likely (OR= 0.47) to be prescribed biologic regimens than patients 
aged 18-44 years. Differences in prescribing patterns by race, BMI, comorbid RA, and 
provider specialty were statistically insignificant. ConClusions: Male gender and 
comorbid PsA were associated with increased likelihood of initial biologic-based 
treatment for newly diagnosed PsO patients. Older age (≥ 65 years) was associated 
with a decreased likelihood of initial treatment with a biologic-containing regimen.
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No differences in improvements in HRQoL were observed with epratuzumab dur-
ing EMBLEM™, potentially due to short term treatment, small sample sizes and 
active SOC therapy. Sustained improvements were observed in the EMBLEM™ OLE, 
consistent with those in the ALLEVIATE RCTs.
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objeCtives: Obesity is associated with many health-related risk factors and is a 
significant economic burden on society. The objectives of this study were to exam-
ine the prevalence of patient-reported comorbidities, productivity loss and health-
related quality of life (HRQoL) across different BMI ranges. Methods: Overweight/
obese patients from the 2012 U.S. National Health and Wellness Survey, a nationally 
representative, online survey of 71,157 respondents aged ≥ 18 years, were catego-
rized and analyzed by their BMI: overweight (BMI> = 25 & < 30 kg/m2), obese class 
I (BMI> = 30 & < 35 kg/m2), obese class II (BMI> = 35 & < 40 kg/m2), and obese class 
III (BMI> = 40 kg/m2). Patients provided information on HRQoL (SF-36v2: mental 
and physical component summary (MCS, PCS) and SF-6D (health utility) scores), 
productivity loss (Work Productivity and Activity Impairment questionnaire) and 
comorbidities (sleep-difficulties, insomnia, pain, anxiety and depression) they expe-
rienced in the past 12 months. Results: Among 45,641 overweight/obese patients, 
49.8% were overweight, 27.9% were obese class I, 12.5% were obese class II, and 
9.8% were obese class III. The proportions of patients experiencing sleep-difficulties 
(overweight: 20.3%; obese class I: 24.6%; obese class II: 28.6%; obese class III: 35.3%), 
pain (overweight: 32.6%; obese class I: 38.1%; obese class II: 42.5%; obese class III: 
48.5%), insomnia, anxiety and depression increased along with BMI increase (all 
p< 0.001). MCS (overweight: 50.0; obese class I: 48.9; obese class II: 47.8; obese class 
III: 46.1), PCS (overweight: 51.1; obese class I: 48.8; obese class II: 46.5; obese class 
III: 43.0) and health utility scores declined with an increase in BMI (all p< 0.001). 
Among employed patients, overall work impairment increased as BMI increased 
(p< 0.001). ConClusions: Data suggests a greater prevalence of pain, depression, 
anxiety, and sleep problems as BMI increases. Increasing BMI is also associated with 
significantly worsening HRQoL. Successful obesity prevention and management 
may help improve patients’ quality of life and productivity.
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objeCtives: Current treatments for systemic lupus erythematosus (SLE) include 
corticosteroids (CS), immunosuppressants (IM), antimalarials (AM) and biologics. 
SLE treatments, in particular CS, are associated with adverse effects which impact 
tolerability and treatment-burden. This study sought to assess the use of CS in 
SLE, and the burden associated with this treatment class. Methods: Data were 
extracted from the Adelphi 2013 Lupus Disease-Specific Programme (a multina-
tional survey of clinical practice). Physicians completed Patient Record Forms (PRFs) 
and underwent face-to-face interviews; patients self-reported data including the 
EQ-5D, Work Productivity & Activity Impairment Index for SLE (WPAI-Lupus) and 
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in Patient Self-
Completion Records (PSCs). Patient eligibility was determined by physicians; disease 
activity and severity were based on physician and patient assessment. Results: 
Data were collected from rheumatologists in the US (n= 97), France (n= 37) and 
Germany (n= 35), including PRFs (550/200/207, respectively) and PSCs (303/109/149, 
respectively). 57%/84%/89% of patients in the US/France/Germany were receiving 
CS treatment. CS were perceived to be equal/superior to AM, IM and biologics in the 
ability to rapidly treat flare and pain but inferior in terms of safety/tolerability and 
inhibition of disease progression. More than half of patients had concerns regard-
ing CS treatment, mainly due to side-effects and fear of long-term use. Patients 
receiving CS had greater resource use (increased IM/biologic use, greater physi-
cian consultation and hospitalisation) and worse HRQoL and activity impairment 
vs non-CS patients (EQ-5D= 0.78 vs 0.87; FACIT-F= 34.41 vs 39.56; WPAI= 23.30 vs 
13.22), but were also associated with worse clinical status (more ‘moderate severe’ 
SLE, more ‘deteriorating’ disease state, more rash/pain/flaring/depression, greater 
organ system involvement). ConClusions: Although a major component of SLE 
standard of care, clear unmet needs are associated with CS use regarding HRQoL 
and resource use. Long-term safety and tolerability are also major areas of concern 
for both physicians and patients.
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objeCtives: Our objective was to determine costs of kidney transplant hospitaliza-
tion in charges billed and payments reimbursed by Medicare based on body mass 
index(BMI). Methods: Retrospective analysis of USRDS and Medicare Claims 
from 2004-2009 for primary Medicare beneficiaries of primary kidney transplant of 
deceased (DD) and living donors (LD) recipients. Subjects were excluded for multiple 
transplants, donor < 5 yo, and transplantation payment < 15,000 U.S. dollars. BMI 
